BeStock  
Stocks › Biotechnology › ACRS

Aclaris Therapeutics ACRS

US equityMarket cap rank #3543Biotechnology
$3.44 −$0.06 (-1.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.44 0.00%
Open$3.44
Prev close$3.50
Day range$3.40 – $3.55
Volume2.19M
Market cap$545.63M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership82.0%-3.84 pts vs. prior quarter
Institutions holding180+6 vs. prior quarter
Insider trades (recent)40 buys / 10 sellsNet buying
Short interest7.47% of floatDays to cover 4.0 · as of 30 Oct 2026
Short-sale volume share24.0%5-day average of daily volume

Short-sale volume as % of daily volume

12%24%35%47%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$1.78M (1 inflow days, 19 outflow days).

Net flow by order size, last 20 sessions

−$1.7MSuper−$57.9KBig−$1.3MMid−$636.4KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 32.9% of shares outstanding.

Largest holders

  • RA Capital Management, L.P.8.02%
  • BML Capital Management, LLC6.91%
  • BlackRock6.54%
  • Deep Track Capital, LP5.89%
  • Frazier Life Sciences Management, LP5.50%
  • FMR4.44%
  • Vivo Capital, LLC4.22%
  • Vanguard Capital Management, LLC3.70%

By investor type

  • VC/PE Fund30.25%
  • Mutual Fund29.22%
  • Hedge Fund20.79%
  • Individual/Insider2.03%
  • Public Company1.04%
  • Private Company0.36%
  • Insurance Company0.16%
  • Government Pension Fund0.11%

Reported short interest has fallen from 9.99% to 7.47% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +6,733,978 4.4%
Artal Group S.A. VC/PE Fund 2026/Q3 +2,025,000 1.3%
Franklin Resources Mutual Fund 2026/Q3 +871,027 0.5%
Putnam LLC Mutual Fund 2026/Q3 +870,952 0.5%
Invesco Capital Management LLC Mutual Fund 2026/Q3 +574,584 0.5%
State Street Global Advisors Mutual Fund 2026/Q3 +440,804 2.3%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +395,736 2.3%
Barclays PLC Public Company 2026/Q3 +381,828 0.3%
BlackRock Mutual Fund 2026/Q3 +339,584 6.5%
Harvest Investment Services, LLC Mutual Fund 2026/Q3 +292,598 0.2%
UBS Asset Management Mutual Fund 2026/Q3 +227,500 0.3%
Frazier Life Sciences Management, LP VC/PE Fund 2026/Q3 +3,804,142 5.5%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +249,775 0.2%
RA Capital Management, L.P. VC/PE Fund 2026/Q3 +5,918,954 8.0%
BlackRock Mutual Fund 2026/Q3 +2,629,943 6.8%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
31 Jul 2026 Roland Kolbeck Chief Scientific Officer Derivative Exercise and Sale -12,385 $5.20 23,990
31 Jul 2026 Roland Kolbeck Chief Scientific Officer Derivative Exercise and Retained +23,990 – 23,990
4 Jun 2026 Vincent Milano Independent Director Derivative Exercise and Retained +11,580 – 28,896
4 Jun 2026 Andrew Schiff Independent Director Derivative Exercise and Retained +11,580 – 25,540
4 Jun 2026 Maxine Gowen Independent Director Derivative Exercise and Retained +11,580 – 33,334
4 Jun 2026 William Humphries Independent Director Derivative Exercise and Retained +11,580 – 45,105
4 Jun 2026 Anand Mehra Independent Director Derivative Exercise and Retained +11,580 – 726,403
4 Jun 2026 Christopher Molineaux Lead Independent Director Derivative Exercise and Retained +11,580 – 69,536
3 Jun 2026 Vincent Milano Independent Director Other Derivative Acquisition +10,987 – 10,987
3 Jun 2026 Vincent Milano Independent Director Other Derivative Acquisition +42,350 $4.71 42,350
3 Jun 2026 Andrew Schiff Independent Director Other Derivative Acquisition +10,987 – 10,987
3 Jun 2026 Andrew Schiff Independent Director Other Derivative Acquisition +42,350 $4.71 42,350
3 Jun 2026 Maxine Gowen Independent Director Other Derivative Acquisition +10,987 – 10,987
3 Jun 2026 Maxine Gowen Independent Director Other Derivative Acquisition +42,350 $4.71 42,350
3 Jun 2026 William Humphries Independent Director Other Derivative Acquisition +10,987 – 10,987
3 Jun 2026 William Humphries Independent Director Other Derivative Acquisition +42,350 $4.71 42,350
3 Jun 2026 Anand Mehra Independent Director Other Derivative Acquisition +10,987 – 10,987
3 Jun 2026 Anand Mehra Independent Director Other Derivative Acquisition +42,350 $4.71 42,350
3 Jun 2026 Christopher Molineaux Lead Independent Director Other Derivative Acquisition +10,987 – 10,987
3 Jun 2026 Christopher Molineaux Lead Independent Director Other Derivative Acquisition +42,350 $4.71 42,350

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 11,572,867 7.5% 4.0
15 Oct 2026 15,027,284 10.2% 3.0
30 Sep 2026 18,191,280 12.4% 6.5
15 Sep 2026 16,075,295 10.9% 6.4
31 Aug 2026 15,180,778 10.3% 8.7
14 Aug 2026 14,710,712 10.0% 7.0

Discussion

No comments yet — be the first to weigh in on ACRS.

Sign in to join the discussion.

Scroll to Top